**Supplementary Figure 2. Data Extraction Form**

**Checklist Economic Evaluation**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **General Part** | | | | |
| **Author:** | | | | |
| **Title:** | | | | |
| **Journal:** | | | | |
| **Year of Publication:** | | | | |
| **Country:** | | | | |
| **Financier:** | | | | |
| **Perspective of Analysis:**  0 mentioned    0 society  0 health care sector  0 insurers  0 institutions  0 clients  0 other, namely…….. | | 0 not mentioned  **Own assessment of analysis:**  0 society  0 health care sector  0 insurers  0 institutions  0 clients  0 other, namely…….. | | |
| **Theoretical background of study:** | | | | |
| **Short description of Self Management Intervention:**  Delivered by who:  What:  To whom:  Where:  How often: | | | | |
| **Short description of Alternative intervention 1:**  Delivered by who:  What:  To whom:  Where:  How often: | | | | |
| **Short description of Alternative intervention 2:**  Delivered by who:  What:  To whom:  Where:  How often: | | | | |
| **Remarks:** | | | | |
| **Follow-up (= time horizon/period of study):** | | | | |
| **Disease Category:**  0 infectious and parasitic diseases, namely……..  0 neoplasm, namely……..  0 endocrine, nutritional and metabolic diseases, namely……..  0 diseases of blood and blood-forming organs, namely:  0 mental disorders, namely……..  0 diseases of the nervous system and sens organs, namely……..  0 diseases of the circulatory system, namely……..  0 diseases of the respiratory system, namely……..  0 diseases of the digestive system, namely……..  0 diseases of the genitourinary system, namely……..  0 childbirth and complications of pregnancy, childbirth and the puerperium, namely……..  0 diseases of the skin and subcutaneous tissue, namely……..  0 diseases of the musculoskeletal system and connective tissue, namely……..  0 congenital anomalies, namely……..  0 certain conditions originating in the perinatal period, namely……..  0 symptoms, signs and ill-defined conditions, namely……..  0 injury and poisoning, namely……..  0 other, namely…….. | | | | |
| **Epidemiological Part** | | | | |
| **Epidemiological design used:**  0 experimental/randomized controlled trial  0 observational  0 case-control study  0 other, namely…….. | | | | |
| **Study size (if possible complete each item):**  0 N (total number of included participants):  0 Number of groups  0 N per group | | | | |
| **Study population:**  0 Prestratification  0 Matching on relevant prognostic factors  0 Eligibility criteria (in- and exclusion criteria)  0 Homogeneity/Similarity in relevant aspects at baseline  0 Documentation of protocol deviations, for example:  0 Withdrawals, N per group:  Due to:  0 Drop-outs, N per group:  Due to:  0 Contamination, N per group:  Due to:  0 Non-compliers, N per group:  Due to:   1. Co-intervention, N per group:   Due to: | | | | |
| **Treatment allocation & treatment**  0 Randomization  0 Treatment allocation concealed | | | | |
| **Adequate measurement and Analysis of effects**  0 Patients blinded  0 Therapist blinded  0 Observer blinded  0 Investigator blinded  0 Intention-to-treat analysis | | | | |
| **Remarks:** | | | | |
| **Economical Part** | | | | |
| **Economic Evaluation Design Used:**  0 Full economic Cost-minimization analysis, costs in monetary terms and effects are assumed equal between interventions  0 Full economic Cost-effectiveness analysis, costs in monetary terms and effects in natural unites (e.g. pain, blood pressure)  0 Full economic Cost-utility analysis, costs in monetary terms and effects in utilities and quality adjusted life years  0 Full economic Cost-benefit analysis, both costs and effects in monetary terms  0 Other, namely…….. | | | | |
| **Costs Identification:** | *Health care costs:*  0 Hospital visits  0 GP visits  0 Other, namely…….. | | *Patient and family costs:*  0 Travel costs  0 Cost of informal care  0 Other, namely…….. | |
| *Cost outside the health care sector:*  0 Productivity costs  0 Other, namely…….. | | *Intervention cost*  0 Yes  0 No | |
| **Costs measurement:**  Which sources are used to measure costs (e.g. questionnaire, diary, hospital records)? | | | | |
| **Cost valuation:**  0 *Valuation of overall costs*  0 Tarrifs  0 Cost price estimations  0 Cost guidelines  0 Other, namely……..  0 *Valuation of productivity losses*  0 Human Capital approach  0 Friction Cost method  0 US Panel approach | | | | |
| **Price year and index**  Which price year is chosen:  Are other costs indexed  0 Yes  0 No | | | | |
| **Effect identification and measurement:**  *Characteristic: Instrument:*  Depression (example) BDI (example) | | | | |
| **Discounting:**  0 Costs  Percentage………%  0 Effects  Percentage………%  0 Costs and Effects  Percentage costs………%  Percentage effects………% | | | | |
| **Synthesis costs and effects:**  0 ICER (Incremental Cost Effectiveness Ratio)  0 NMB (Net Monetary Benefit)  0 NET cost (if Cost Benefit Analysis is used)  0 Other, namely…….. | | | | |
| **Uncertainty:**  0 Test sample uncertainty  0 via bootstrap  0 via Fieller  0 Test variable uncertainty via sensitivity  0 one-way sensitivity analysis  0 two-way sensitivity analysis  0 multiple sensitivity analysis  0 Methodological sensitivity analysis overcome by following a guideline  0 following this guideline:  0 Other, namely…….. | | | | |
| **Visualization of results:**  0 Cost Effectiveness Plane (CE Plane)  0 Cost Effectiveness Acceptability Curve (CEAC)  0 Other, namely…….. | | | | |
| **Main results (in two or three sentences, with numbers - e.g. ICER - if possible):** | | | | |
| **Remarks:** | | | | |
| **CHEC List** | | | | |
| **Item: Yes No** | | | | |
| 1. Is the study population clearly described?  2. Are competing alternatives clearly described?  3. Is a well-defined research question posed in answerable form?  4. Is the economic study design appropriate to the stated objective?  5. Is the chosen time horizon appropriate to include relevant costs and consequences?  6.Is the actual perspective chosen appropriate?  7. Are all important and relevant costs for each alternative identified?  8. Are all costs measured appropriately in physical units?  9. Are costs valued appropriately?  10. Are all important and relevant outcomes for each alternative identified?  11. Are all outcomes measured appropriately?  12. Are outcomes valued appropriately?  13. Is an incremental analysis of costs and outcomes of alternatives performed?  14. Are all future costs and outcomes discounted appropriately?  15. Are all important variables, whose values are uncertain, appropriately subjected to sensitivity analysis?  16. Do the conclusions follow from the data reported?  17. Does the study discuss the generalizability of the results to other settings and patient/ client groups?  18. Does the article indicate that there is no potential conflict of interest of study researcher(s) and funder(s)?  19. Are ethical and distributional issues discussed appropriately? | | | | 0 0  0 0  0 0  0 0  0 0  0 0  0 0  0 0  0 0  0 0  0 0  0 0  0 0  0 0  0 0    0 0  0 0    0 0    0 0 |